PHARMACEUTICAL 2011

ELI Lilly Co
Rank 22 of 31



PHARMACEUTICAL 2011

ELI Lilly Co
Rank 22 of 31

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 36% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 253%, being 35% points below the market average of 287%.

Input Variable	Value in 1000 USD
Assets, Current	14,840,000
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,101,400
Liabilities, Non-Current	11,487,200
Other Assets	8,220,700
Other Compr. Net Income	-198,200
Other Expenses	6,068,900
Other Liabilities	0
Other Net Income	0
Other Revenues	23,076,000
Property and Equipment	7,940,700
Research and Development	4,884,200
Selling, General and Administrative Expense	7,053,400

Output Variable	Value in 1000 USD
Assets	31,001,400
Liabilities	18,588,600
Expenses	18,006,500
Revenues	23,076,000
Stockholders Equity	12,412,800
Net Income	5,069,500
Comprehensive Net Income	4,970,400
BaseVar	45,435,350
ECR before LimitedLiability	129%
Economic Capital Ratio	253%